Citation: Herder M (2017) What Is the Purpose of the Orphan Drug Act? PLoS Med 14(1): e1002191. https://doi.org/10.1371/journal.pmed.1002191
Published: January 3, 2017
Copyright: © 2017 Matthew Herder. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: MH is currently the Principal Investigator of Grant #EOG 123678 funded by the Canadian Institutes of Health Research entitled “Emerging Health Researchers and the Commercialization of Academic Science.” The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The author has declared that no competing interests exist.
Abbreviations: FDA, Food and Drug Administration; ODA, Orphan Drug Act; R&D, research and development
Provenance: Commissioned; not externally-peer reviewed
The Orphan Drug Act (ODA) , first enacted in the United States in 1983, was set up to encourage the development of drugs for rare diseases. At that time, drug therapies for such diseases were rarely developed. Three decades later, a growing proportion of industry research and development (R&D)  and regulatory drug approvals  target diseases affecting fewer than 200,000 persons in the United States, the prevalence-based threshold of rare disease under the ODA.
In a new article published in PLOS Medicine, Aaron Kesselheim and colleagues document an embedded trend: within the increasing number of drug approvals targeting rare diseases, there is a substantial minority of biomarker-defined subsets of more common diseases, especially cancers . Commentators have long worried about this phenomenon of “salami slicing” common diseases for the purposes of drug approval because of the market advantages that orphan drug status confers [5,6]. Due to lower R&D costs (e.g., relatively small clinical trials or observational studies), expedited regulatory reviews, and minimal competition even after patent and ODA market protection expire, rare-disease-targeting orphan drugs are now amongst the most expensive and profitable drugs on the market in the world .
Most of the policy and scholarly response to the orphan drug pricing problem to date has been to explore new ways to evaluate orphan drug performance following regulatory approval [8,9]. However, there is little indication that health care payers are successfully pushing back on drug price points. Meanwhile, the findings of Kesselheim and colleagues underscore how the operation of the ODA upstream—at the point of regulation—serves to expand the scope of the problem. With the increasing ability to more precisely identify biomarker-defined subsets of disease, it is perhaps time to re-examine how the ODA distinguishes rare versus common forms of disease or, even more fundamentally, what the ODA is meant to achieve.
The Definition of an Orphan
Before the ODA became law, Congress heard diverse views about which R&D “orphans” the legislation should attempt to rescue . Some witnesses focused on rare diseases during Congressional hearings, whereas others advocated for “orphan medical devices and medically necessary foods” . Still others spoke in favor of “drugs for less developed countries,” or vaccines, which manufacturers had moved away from due to high product liability concerns at that time. Worried that this lack of consensus might undermine the bill’s progress, the ODA’s authors made a political choice to focus on rare diseases .
Even so, the ODA did not originally include a prevalence-based definition of rare disease. Rather, the ODA defined a “rare disease or condition” as one that “occurs so infrequently in the United States that there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from the sales in the United States of such drug” . Orphan drug status was therefore not granted simply because it targeted a rare disease; rather, the disease had to be rare enough to occasion market neglect.
However, just as the Food and Drug Administration (FDA) began making “determinations” about whether a given disease met the ODA’s test of market neglect, the FDA’s task was grossly simplified. In 1984 the ODA was amended, redefining rare diseases as those affecting “less than 200,000 persons in the United States” (the prevalence-based definition) or more than 200,000 persons, but for whom “there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will be recovered from the sale in the United States” (a commercial viability definition) .
With that change, the FDA went from requiring evidence of the commercial non-viability of orphan drug R&D to assuming commercial non-viability, provided the drug targeted fewer than 200,000 persons. Numerous studies that suggest that orphan drugs are actually more profitable than non-orphan drugs call this underlying assumption into serious question [7,13,14]. Avoiding any accounting of their actual R&D costs, nearly all of the more than 2,000 orphan drug designations sought and obtained by drug-makers between 1983 and 2011 fall within the prevalence-based definition . And without upfront scrutiny of the relationship between disease prevalence and anticipated profits, drug manufacturers are routinely able to price orphan drugs at US$100,000–US$200,000 per patient per year, needing only 5,000–10,000 patients to generate US$1 billion in annual revenues.
Revise and Reclaim the ODA
What should be done? One idea is for the FDA to try yet again to cut down on the practice of salami slicing and, in turn, to better discriminate between genuine and artificial rare diseases. In 1992, the FDA first purported to curb salami slicing by requiring that, for subsets of common diseases to be considered rare, they needed to be “medically plausible” , a term it failed to define. Twenty-one years later, the FDA finally promulgated more promising regulations  that hold drug manufacturers to a higher standard of evidence. When seeking an orphan drug indication, manufacturers must now show not only why one subset of a disease should be targeted by their drug, but also why the drug is inappropriate outside the selected subset . However, the findings of Kesselheim and colleagues  suggest that these new regulations—or the FDA’s application of them—may not be adequate to the task. Another potentially more fruitful approach is to limit orphan drug designation to disease pathways rather than the rarity of the disease per se .
Fundamentally, though, the purpose of the ODA merits re-examination. At bottom, the ODA was intended to redistribute resources to medical needs that would otherwise be marginalized by market forces. With the introduction of the prevalence-based definition of rare disease, we began losing sight of the ODA’s core, redistributive function.
To restore that function, we need to open up the very concept of an orphan disease or condition under the ODA and resume the scrutiny of claims of market-mediated, unmet medical need instead of policing the ever-shifting boundaries of disease. After all, “the category of orphan diseases bears no essential relationship to their prevalence, morbidity, or mortality” . Markets also discourage a range of other research areas, including research involving pregnant women (because of perceived risks to the foetus) , comparative effectiveness research that seeks to assess the risks and benefits of competing drug treatments (because of the difficulty involved in patenting that type of information) , and research into diseases that disproportionately affect the world’s poor (because of the population’s low purchasing power) . All of these areas of research carry tremendous social welfare gains; however, they have been effectively orphaned by the ODA’s current focus on rare diseases. Policymakers can reclaim the ODA by removing the prevalence-based definition of a rare disease, allowing other areas of research to qualify as orphans and reviving the FDA’s original, albeit short-lived, task of scrutinizing the demonstrable level of market neglect of the affected population, whether for reasons of rarity, poverty, gender, or otherwise. Waiting to see what comes down the pipe and then attempting to negotiate better prices for orphan drugs seems unlikely to succeed as a strategy for securing access to marginalized, but socially valuable, health innovations.
The author would like to thank Aidan Hollis and Catherine Bryan for helpful comments on a draft of this Perspective article.
- 1. Orphan Drug Act of 1983. Pub L. No. 97–414, 96 Stat. 2049.
- 2. Lazonick W, Tulum Ö. US biopharmaceutical finance and the sustainability of the biotech business model. Research Policy. 2011 Nov;40(9):1170–87.
- 3. Silverman, Ed. FDA designated a record number of orphan drugs last year [Internet]. STAT. 2016 [cited 2016 Sep 12]. https://www.statnews.com/pharmalot/2016/02/11/fda-designates-record-number-of-orphan-drugs/
- 4. Kesselheim A, Treasure CL, Joffe S. Biomarker-defined subsets of common diseases: policy and economic implications of Orphan Drug Act coverage. PLoS Med. 2016;14(1):e1002190.
- 5. Rai AK. Pharmacogenetic interventions, orphan drugs, and distributive justice: The role of cost-benefit analysis. Social Philosophy and Policy. 2002;19(02):246–70.
- 6. Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses. Am JL & Med. 2005;31:365–80.
- 7. Meekings KN, Williams CSM, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discovery Today. 2012 Jul;17(13–14):660–4. pmid:22366309
- 8. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74. pmid:23013790
- 9. Fellows GK, Hollis A. Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach. Orphanet Journal of Rare Diseases. 2013;8:180. pmid:24237605
- 10. Waxman HA. The history and development of the Orphan Drug Act. In: Scheinberg IH, Walsh JM, editors. Orphan Diseases and Orphan Drugs. Manchester University Press; 1986.
- 11. Orphan Drug Act of 1983, Pub. L. No. 97–414, 96 Stat 2049 (Jan. 4, 1983). § 526(a)(2).
- 12. Health Promotion and Disease Prevention Amendments of 1984, Pub. L. 98–551, 98 Stat 2815 (1984), § 4.
- 13. Simoens S. Pricing and reimbursement of orphan drugs: The need for more transparency. Orphanet Journal of Rare Diseases. 2011;6:42. pmid:21682893
- 14. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: Rare disease research stimulator or commercial research opportunity? 2010;95(2):216–228. pmid:20036435
- 15. Kesselheim AS. An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences. Milbank Quarterly. 2011 Sep 1;89(3):450–502. pmid:21933276
- 16. Orphan Drug Regulations (Final Rule) 57 Fed. Reg. 62,076 (Dec. 29, 1992).
- 17. Gibson S, Tigerstrom B von. Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada. J Law Biosci. 2015 Jul 13;2(2):263–91. pmid:27774196
- 18. Orphan Drug Regulations (Final Rule) 78 Fed. Reg. 35,117 (June 12, 2013).
- 19. Warren KS. The great neglected diseases of mankind, or All the world's an orphanage. In: Scheinberg IH, Walshe JM, editors. Orphan Diseases and Orphan Drugs. Manchester University Press; 1986.
- 20. Baylis F. Pregnant women deserve better. Nature. 2010 Jun 10;465(7299):689–90. pmid:20535185
- 21. Kapczynski A, Syed T. The Continuum of Excludability and the Limits of Patents. Yale Law Journal. 2013;122(7):1900–63.
- 22. Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, et al. Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health. 2001 Nov;6(11):945–51. pmid:11703850